Oric Pharmaceuticals (ORIC) Stock: Buy, Sell, or Hold?
ORIC - Oric Pharmaceuticals, Inc. Common Stock
$13.63
-0.22 (-1.59%)
▼
5d:
+6.73%
30d:
+2.25%
90d:
+12.64%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 12, 2026
19d
Get Alerted When ORIC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ORIC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ORIC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ORIC is currently trading at $13.63, which is considered extended relative to its 30-day fair value range of $12.01 to $13.31.
Technical Outlook: Technically, ORIC is in a strong uptrend. Immediate support is located at $11.20, while resistance sits at $14.31.
Market Sentiment: ORIC scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.64 (+58.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ORIC is in a strong uptrend. Immediate support is located at $11.20, while resistance sits at $14.31.
Market Sentiment: ORIC scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.64 (+58.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$12.01 -
$13.31
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 58.8% below Wall St target ($21.64)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$12.01 -
$13.31
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$11.20
Resistance Level
$14.31
Current Trend
Strong Uptrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.15
Wall Street Target
$21.64
(+58.8%)
Share & Embed Analysis
Last updated: October 23, 2026 7:44 AM ET
Data refreshes hourly during market hours. Next update: 8:44 AM
Data refreshes hourly during market hours. Next update: 8:44 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORIC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$139 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
25 analysts |
$1153 | 52 HOLD |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 63 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
17 analysts |
$141 | 56 HOLD |
|
CLYM
Climb Bio Inc |
STRONG BUY
15 analysts |
$28 | 63 BUY |
